Advertisement

 

 

Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue.

Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue.
Author Information (click to view)

Halstead SB,


Halstead SB, (click to view)

Halstead SB,

Advertisement

The Lancet. Infectious diseases 2017 07 12() pii S1473-3099(17)30362-6
Abstract

Newly proposed candidate Zika virus vaccines might or might not succeed in raising safe, effective, and durable protection against human Zika virus infections or syndromes. Analyses of a clinically tested and licensed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection failure. Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occur with some Zika virus vaccine designs. A successful Zika virus vaccine requires challenge experiments that are done at long intervals after immunisation and that identify protection as the absence of viraemia and the absence of an anamnestic antibody response. T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines.

Submit a Comment

Your email address will not be published. Required fields are marked *

fourteen − eight =

[ HIDE/SHOW ]